---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-23-105679"
form_type: "8-K"
ticker: "AGIO"
cik: "0001439222"
company_name: "AGIOS PHARMACEUTICALS, INC."
filed_at: "2023-04-19T23:59:59+00:00"
generated_at: "2026-06-16T23:31:46.800770+00:00"
event_type: "leadership"
sentiment: "neutral"
materiality_score: 0.45
calibrated_materiality_score: 0.45
confidence: "high"
source: SEC EDGAR
---

# Agios director Paul Clancy to retire; Jeff Capello elected to board, to chair Audit Committee

## Summary
- Paul Clancy will not stand for re-election at 2023 Annual Meeting; ceases as Audit Committee chair and Compensation & People Committee member.
- Jeff Capello elected as class II director effective at 2023 Annual Meeting; appointed Audit Committee chair.
- Capello receives $50,000/yr director cash retainer plus $20,000/yr for Audit Chair role; initial equity grant of stock options ($472,500 Black-Scholes) and RSUs ($157,500).
- Capello enters into standard indemnification agreement with the company.

## SEC filing metadata
- accession: 0001193125-23-105679
- form_type: 8-K
- ticker: AGIO
- cik: 0001439222
- company_name: AGIOS PHARMACEUTICALS, INC.
- filed_at: 2023-04-19T23:59:59+00:00
- event_type: leadership
- sentiment: neutral
- materiality_score: 0.45
- calibrated_materiality_score: 0.45
- confidence: high
- sec_items: 5.02
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1439222/000119312523105679/0001193125-23-105679-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1439222/000119312523105679/d499411d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-23-105679
- JSON: https://secwatch.observer/filing/0001193125-23-105679.json
- Plain text: https://secwatch.observer/filing/0001193125-23-105679.txt

## Key facts
- Executive change
  Paul Clancy resigned as Director at AGIOS PHARMACEUTICALS, INC..
  - Action: resigned
  - Role: Director
  source text: On April 17, 2023, Paul Clancy notified Agios Pharmaceuticals, Inc. (the “Company”) of his decision not to stand for re-election to the Board of Directors (the “Board”) of the Company when his current term expires at the Company’s 2023 Annual Meeting of Stockholders.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1439222/000119312523105679/0001193125-23-105679-index.htm
- Executive change
  Jeff Capello was elected as Director at AGIOS PHARMACEUTICALS, INC..
  - Action: elected
  - Role: Director
  source text: On April 18, 2023, the Board of the Company, upon the recommendation of the Nominating and Corporate Governance Committee of the Board (the “Corporate Governance Committee”), elected Jeff Capello as a director, effective as of the date of the Corporation’s 2023 Annual Meeting of Stockholders (the “Effective Date”).
  evidence_url: https://www.sec.gov/Archives/edgar/data/1439222/000119312523105679/0001193125-23-105679-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.